About: Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.09 (-1.88%)
FHTX NASDAQ Foghorn Therapeutics Inc
Foghorn Therapeutics Inc share price
Atividade de preço de FHTX
Último preço
$ 2,090
Variação (24h)
-0,04 USD (1,88%)
Volume
396.88K
Volume (média 4 sem.)
-
Abertura
$ 2,16
Variação do dia
$ 2,06 - $ 2,20
Fechamento anterior
$ 2,13
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
FHTX price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals